menu
    • menu
    [{"orgOrder":0,"company":"Oncodesign Services","sponsor":"Tiumbio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Oncodesign Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncodesign Services \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Oncodesign Services \/ Oncodesign"},{"orgOrder":0,"company":"Oncodesign Services","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign Services","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncodesign Services \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign Services \/ Servier"},{"orgOrder":0,"company":"Oncodesign Services","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncodesign Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncodesign Services \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Oncodesign Services \/ Oncodesign"},{"orgOrder":0,"company":"Oncodesign Services","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign Services","amount2":0.35999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Oncodesign Services \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign Services \/ Servier"},{"orgOrder":0,"company":"Oncodesign Services","sponsor":"SEngine Precision Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign Services","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncodesign Services \/ Oncodesign","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign Services \/ Oncodesign"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncodesign Services

    Menu

    Oncodesign Services

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Debiopharm and Oncodesign Launch Strategic Collaboration for Radiopharmaceuticals

                            Details : Under the licensing agreement, Oncodesign will holds the rights of AbYlink technology aiming for drug discovery and preclinical services.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 24, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Servier

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Servier Collaborates in The Treatment of Pancreatic Cancer

                            Details : Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 22, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Servier

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : SEngine Precision Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personaliz...

                            Details : SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix® inhibitor series into drug candidates that are likely to be effective in the clinic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 08, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : SEngine Precision Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Recipient : Tiumbio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

                            Details : Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Recipient : Tiumbio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed

                            Oncodesign Services

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Servier

                            Deal Size : $363.3 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oncodesign and Servier Reach a Key First Milestone

                            Details : The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $3.3 million

                            February 17, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Servier

                            Deal Size : $363.3 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth